a.HRD is present in approximately 50% of patients with high-grade serous ovarian cancer.

b.The incidence of HRD-positive patients is 2-3.5 times that of BRCA1/2-positive patients alone, which helps to find more benefit groups of PARP inhibitors.

c.Patients with high HRD values are more sensitive to PARP inhibitors than those with low HRD values.

d.Patients with high HRD values benefit from platinum-based chemotherapy regimens more than those with low HRD values.

Certification

① Design a gene list with reference to the University of Washington consensus, NCCN guidelines and other institutional guidelines, and comprehensively include 85 related genes.

② Referring to the ChinaMap database of 10,000 individuals in China, screening 41,000+ high-quality SNPs loci in the Chinese population.

Comprehensive

The scoring algorithm optimized for the Chinese population simultaneously analyzes the three genomic instability indicators of LOH, TAI and LST to provide a comprehensive GIS score.

Accuracy

Ultra-high sequencing depth, and low-frequency sites are not missed.

High quality

Imported raw materials are used for testing to ensure the quality of testing from the source.

Cancer patient：Patients with breast cancer (triple negative breast cancer), ovarian cancer, prostate cancer, pancreatic cancer and peritoneal cancer etc.

Patients on medication： PARP Inhibitor medication patients

Personalized treatment of patients：Individualized treatment of patients with platinum-based chemotherapy or other homologous recombination inhibitors